Navigation Links
Pfizer Receives Complete Response Letter from FDA for REMOXY®
Date:6/24/2011

CUPERTINO, Calif., June 24, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Pfizer Inc. (NYSE: PFE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY®, a controlled-release form of oxycodone designed to discourage common methods of tampering.  Pfizer stated that it is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

"Pfizer has an experienced team of scientists dedicated to resolving the remaining issues," stated James E. Brown, D.V.M., President and CEO of DURECT Corporation.  "The misuse and abuse of pain medications is a widespread problem in this country and we will continue to support Pfizer in their efforts to address this important public health and safety issue."

REMOXY, based on DURECT's ORADUR® technology, is an investigational drug that is a unique, controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential risks of unintended use.  Approximately 50 million Americans suffer from persistent pain each year, according to the American Pain Foundation.

About ORADUR® Technology

ORADUR is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of resisting common methods of prescription drug misuse and abuse compared to other controlled release dosage forms on the market today.

Corporate Relationships

In December 2002, DURECT licensed to Pain Therapeutic
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Endo International plc (NASDAQ: ... revenues of $719 million, an increase of 1 percent ... Endo reported net income of $21 million in the ... million in the second quarter of 2013.  As detailed ... for the three months ended June 30, 2014 increased by ...
(Date:7/31/2014)... July 31, 2014 Marken announced today the ... to meet the clinical trial logistics growth in Central ... expanded facility will continue to serve as a regional ... and from the region, and will provide additional storage ... will combine its office and warehouse into a single ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Marken Expands Miami Regional Logistics Center 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2
... Genetic Technologies Limited (ASX: GTG; NASDAQ: ... agreement to jointly develop a new cancer profiling product ... Under the collaboration Genetic Technologies will use ... world-leading pharmaceutical company to develop specific and novel genetic ...
... If your medicine has expired, it may not provide ... FDA pharmacist Ilisa Bernstein explains how expiration dates help ... work as intended. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ... Sign up for e-mail notices of new FDA Consumer ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
(Date:7/31/2014)... medical and nursing school researchers hope to drastically ... participate in clinical trials, a critical step in ... For various reasonsincluding a lack of awareness that ... patients take part in trials of experimental therapies. ... who are eligible still don,t enroll, according to ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 Reputation ... launched a new service named ‘Remove Bad Reviews’. The ... bad reviews are published on various review sites. ... the world of internet marketing, the sites that allow ... competitors in order to tailor the service. , ...
(Date:7/31/2014)... Mountain View, Calif. and Las Vegas, Nevada (PRWEB) July ... a partnership with LaunchKey to provide next generation authentication ... a simple and secure way to utilize hardware protected ... an enormous problem in the Internet's reliance on password-based ... of hacks and global data breaches taking place around ...
(Date:7/31/2014)... FITNESS SF, a growing chain of health clubs ... all locations to Motionsoft’s full cloud-based product ... a leading provider of club management solutions, and specializes ... services for health and wellness centers. MoSo is Motionsoft’s ... bundled with the MoSo Pay secure billing solution and ...
(Date:7/31/2014)... 2014 T.E.N., a technology and ... finalists and winners Wednesday evening, July 30, at ... Gala at the Westin St. Francis in San ... security for the BlackLine Systems, was selected as ... winner for the ISE® West Region. As the ...
Breaking Medicine News(10 mins):Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 2Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 3Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:FITNESS SF Upgrades Motionsoft Software to Include Entire Product Lineup: MoSo + MoSo Pay + MyClub 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4
... a promising treatment, according to a new study. Radio frequency ablation ... current is then passed through the electrode // to heat the ... not only respond to the treatment but also do not appear ... the standard of care for kidney cancer has been removal of ...
... a significant improvement in treatment for a specific type of ... typically treated by // removal of the testicle followed by ... cancer in another organ up to 20 years later. ... course of the drug carboplatin and more than 900 patients ...
... distributing a new vaccine to children. Researchers found that ... pneumococcal disease (pneumonia or meningitis) decreased among both // ... among whites and 8,780 fewer cases occurred among blacks ... 1998 and 1999. Before the introduction of the vaccine, ...
... function that can cause death within days or even ... to keep patients alive long enough that the liver ... available for transplantation. About 80 percent of patients will ... bioartificial liver along with pig stem cells significantly reduced ...
... A recent study, found that people who get lots of ... as much bladder cancer as those who take in relatively ... prove to be // an important safeguard against heart attacks. ... show any protective effect .Now, some think the vitamin may ...
... find out sooner than later if they have the disease. At ... test. But since PSA levels normally go up and down over ... reading is and what may just be normal for any particular ... to determine whether they have cancer or not. ,Researchers ...
Cached Medicine News:Health News:Vitamin E Found To reduce bladder cancer risk 2
... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
The automated and pivoting M2 hand-piece incorporates two powerful, independent electric motors : one controls the blade oscillation at 15,000 RPM and the second controls the high-torque advance of t...
... Give patients the best potential for ... ACRYSOF IQ IOL compensates for spherical aberration ... the periphery. This is accomplished without increasing ... analyzed to create a design that provides ...
... Optics Aspheric Lens System can revolutionize ... all your cataract patients will want ... and contrast sensitivity. With a revolutionary ... consistently deliver superior optical performance to ...
Medicine Products: